Electroacupuncture for Cognitive Toxicity in Cancer Survivors: Assessing Implementation, Cost, and Effectiveness for Integration

Inclusion Criteria: Survivor participants * Aged 21-85 years * Documented cancer diagnosis in electronic health records * Perceived by the survivor or oncology care provider that cognitive function has worsened since cancer diagnosis and/or beginning of cancer treatment * Able to understand English or Mandarin * Able to provide informed consent Stakeholder participants * Aged ≥21 years * Identified as having a relevant role, experience, or perspective relating to the delivery, referral, coordination, or implementation of EA or supportive cancer care in the study context * Able to provide informed consent Exclusion Criteria: Survivor participants * Presence of brain metastases * Severe needle phobia * Known bleeding disorder (e.g. hemophilia, von Willebrand disease, thrombocytopenia). * Current use of antiplatelet or anticoagulant therapy (e.g. aspirin, clopidogrel, warfarin, enoxaparin, rivaroxaban, dabigatran) * Known blood-borne communicable disease (e.g. hepatitis B, hepatitis C, human immunodeficiency virus) * Presence of a pacemaker or other electronic implant, or a history of epilepsy * Current acupuncture treatment or acupuncture received within the past 3 months * Current pregnancy, planned pregnancy over the next 5 months, or breastfeeding. * Incapable of providing informed consent * Unable to complete study procedures Stakeholder participants * Incapable of providing informed consent * Unable to complete study procedures